Global supply chains in the pharmaceutical industry are under new pressure as geopolitical dynamics shift costs, timelines, and long-term planning. Drug developers in Europe and other international markets are seeking ways to secure reliable access to the United States, the world’s largest pharmaceutical market. Partnering with a U.S.-New Jersey-based contract development and manufacturing organization (CDMO) like Ascendia Pharmaceutical Solutions provides balance for many in this tumultuous market, in addition to being Fast, Flexible, and First-time right! Providing stability, speed, confidence, and TRUST in these uncertain times.
The Ascendia Pharmaceutical Solutions Advantage as a United States CDMO
Ascendia Pharmaceutical Solutions operates a 60,000 square foot facility close to Newark International Airport possesses the skills & resources required to advance your program from pre-formulation development, analytical testing, microbiology, quality, and cGMP manufacturing, aseptic and non-aseptic projects.
This integrated model allows projects to launch in as little as two weeks. Many large CDMOs are unable to match this. By consolidating all teams and infrastructure in one location, Ascendia Pharmaceutical Solutions delivers faster timelines and mitigates risks during technology transfer and scale-up.
Pharmaceutical Tech Transfer Without Delays
Tech transfer and scale-up are often among the highest-risk phases in pharmaceuticals. Ascendia Pharmaceutical Solutions eliminates common bottlenecks by pairing formulators and manufacturing operators early in projects. This approach decreases the common risks associated with formulations being “thrown over the proverbial wall,” as cited by Robert Bloder, the Chief Business Officer at Ascendia Pharmaceutical Solutions. This continuity reduces risk, increases efficiency, and avoids delays caused by fragmented handoffs between department multi-site CDMO models where the knowledge base is scattered.
Specialized Expertise for Complex Formulations
Ascendia Pharmaceutical Solutions has established expertise across oral, injectable, ophthalmic, and topical dosage forms. The company’s proprietary technology platforms AmorSol®, EmulSol®, LipidSol®, and NanoSol® address critical challenges in solubility, stability, and bioavailability.
The facility includes specialized equipment such as the only NETZSCH Vakumix aseptic nanomilling system available in North America within a CDMO. Ascendia Pharmaceutical Solutions also supports lipid nanoparticle development, long-acting injectables, and other complex modalities with in-house analytical testing and quality oversight.
Securing Pharmaceutical Supply Chains in the U.S.
Global drug developers seeking to protect their most valuable programs are increasingly transferring projects to the United States. Ascendia Pharmaceutical Solutions provides a secure U.S.-based contract manufacturing option with specialized expertise, modern infrastructure, and the ability to execute quickly.
Fast. Flexible. First Time Right.
Ascendia Pharmaceutical Solutions delivers pharmaceutical contract manufacturing in the U.S. with speed, flexibility, and a proven record of execution. For global companies navigating uncertainty, the organization offers a direct and reliable path to secure manufacturing, safeguard supply chains, and accelerate clinical and commercial timelines.
Schedule a Meeting with Ascendia Pharmaceutical Solutions
Learn how U.S.-based pharmaceutical contract manufacturing with Ascendia Pharmaceutical Solutions can support your development and manufacturing needs. Contact the team today to schedule a meeting.